WEST HARRISON, NY, United States, via ETELIGIS INC., 11/25/2014 – – The race for BioSig Technologies, Inc. (OTCQB: BSGM) to record abnormal heartbeat wave signals and significantly improve innovation-starved arrhythmia treatment is described in the November 20, 2014 issue of Flaherty Special Situation Newsletter. (Also in this issue is our Follow Up: Remembering the fairy tale life of one of America’s first female financial writers, courageous Clare Reckert of The New York Times.)
Executive Chairman Ken Londoner and President and CEO Gregory D. Cash are transitioning BioSig Technologies, Inc. to make the important transition from an all R&D development company to go commercial. BioSig’s PURE™ System can greatly improve the $3 billion catheter-based electrophysiology (EP) market for treatment of heart patients. Innovative signal recording of clearer intra-cardiac signals will enable electrophysiologists doing their surgeries to see problem areas that they struggle with today using older technology.
BioSig’s technology platform has been demonstrated at several leading U.S. teaching hospitals and research centers. Animal studies have been completed and human clinical trials are in the planning stage. Two patents have been filed. After a medical device application 510(k) has been approved, a commercial launch is planned in 2016.
The complete sponsored special situation containing our BioSig Technologies report can be found archived on our Flaherty Financial News website at http://www.flahertyfinancialnews.com/ .
Direct Server Link To The Report:
Server Link to the Report – With the Modern Social Share Buttons:
About Flaherty Financial News Inc.:
Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of interesting public companies. FFN was launched in February 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years and also Editor-in-Chief of Equities Special Situations, Bob had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. He is also an award-winning retired Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time Forbes record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School. A former president of the New York Financial Writers’ Association, Bob is a co-founder of their annual student scholarship program and their annual award for significant long-term achievement in financial journalism.
About BioSig Technologies, Inc.:
Bio Sig is a medical device company that has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology marketplace. Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig is preparing to commercialize its PURE™ System. It is a next generation surface electrocardiogram and intra-cardiac multi-channel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets. These are areas of tissue to destroy that otherwise create an abnormal heart rhythm disturbance called arrhythmia.
This news release contains “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of l995) regarding the special situation report on BioSig Technologies, Inc. and its future business plans. These statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of all of the companies to be materially different than those implied by these forward-looking statements. Flaherty Financial News Inc. and BioSig Technologies, Inc. have and undertake no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in their expectations of future events. Our full disclaimer and safe harbor statement appears in our newsletter.
Flaherty Financial News Inc.
Brian D. Flaherty, President and Publisher
Tel: (914) 539-0688
For more information on BioSig Technologies, Inc. please visit their website, www.biosigtech.com or contact:
Jody Cain, Senior Vice President
Financial Profiles, Inc.
SOURCE: Flaherty Financial News, Inc.